Skip to content

Globus Medical

US · GMED #1454 by market cap Listed 1970
66.89 -1.71 -2.49%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.99 Cheap vs history 19th percentile
5-year average 2.80 · #54 of 126 in Medical Devices
P/E ratio 17.77 Cheap vs history 1st percentile
5-year average 63.63 · forward 16.00 · #12 of 39 in Medical Devices
P/S ratio 3.04 Cheap vs history 4th percentile
5-year average 5.07 · forward 3.00 · #73 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Globus Medical (GMED) 8.86B 16.48 1.85 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value78.76 Economic moatNone UncertaintyLow

Trading 17.8% below Morningstar's fair value estimate.

Fair value

Globus Medical Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $78.76 per share, which is reinforced by this estimate's low uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's solid growth bolsters our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 34.4% lies in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's free cash flow to sales ratio of 0.3, for example, ranks in the top 10% compared with peers globally. This company's ability to turn revenue into free cash flow is strong, highlighting its compelling relative profitability. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Globus Medical discussion 0 comments

Add a comment